Application No.: 10/659,531

Office Action Dated: October 25, 2004

This listing of claims will replace all prior versions, and listings, of claims in the application.

PATENT

Listing of Claims

1. (original) A compound of Formula I:

$$R^{1} \longrightarrow 0 \longrightarrow N \longrightarrow (CH_{2})_{n} \longrightarrow R^{3}$$

$$X - Y$$

$$I$$

wherein

X-Y is $-N=C(R^4)$ -, -NH-C(O)-, -NH-C(O)-, -NH-C(S)- or $-NH-S(O)_2$ -;

Z is O, S or NR⁵, in which R⁵ is hydrogen or alkyl of 1 to 6 carbon atoms;

R¹, R² and R³ are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

R⁴ is hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms; the dotted line represents an optional double bond; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. (*original*) A compound according to claim 1, wherein R⁴ is hydrogen, amino or alkyl of 1 to 6 carbon atoms.

Application No.: 10/659,531

Office Action Dated: October 25, 2004

3. (*original*) A compound according to claim 1, wherein R⁴ is hydrogen or alkyl of 1 to 3 carbon atoms.

PATENT

- 4. (original) A compound according to claim 1, wherein X-Y is -NH-C(O)-.
- 5. (original) A compound according to claim 1, wherein Z is NR⁵.
- 6. (original) A compound according to claim 1, wherein the dotted line is a double bond.
- 7. (original) A compound according to claim 1, wherein n is 0.
- 8. (original) A compound according to claim 1 having Formula Ia:

Ia

or a pharmaceutically acceptable salt thereof.

- 9. (*original*) A compound according to claim 1, wherein R⁵ is hydrogen or alkyl of 1 to 3 carbon atoms.
- 10. (original) A compound according to claim 1, wherein R⁵ is hydrogen or methyl.
- 11. (*original*) A compound according to claim 1, wherein R¹ is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
- 12. (*original*) A compound according to claim 1, wherein R¹ is hydrogen, halo or alkoxy of 1 to 6 carbon atoms.

Application No.: 10/659,531

Office Action Dated: October 25, 2004

- 13. (original) A compound according to claim 1, wherein R¹ is hydrogen.
- 14. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.

PATENT

- 15. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms.
- 16. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, cyano or halogen.
- 17. (*original*) A compound according to claim 1, wherein R¹ is hydrogen, halo or alkoxy of 1 to 6 carbon atoms, R² and R³ are hydrogen, cyano or halogen, R⁴ is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR⁵, R⁵ is hydrogen or alkyl of 1 to 3 carbon atoms and n is 0.
- 18. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.
- 19. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.

PATENT

DOCKET NO.: WYNC-0329 (AM101205)

Application No.: 10/659,531

Office Action Dated: October 25, 2004

20. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.

- 21. (*original*) A compound according to claim 1, wherein said compound is 3-{1-[(2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl)methyl]-1,2,3,6-tetrahydropyridin-4-yl}-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
- 22. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(7-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.
- 23. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl}-2-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine or a pharmaceutically acceptable salt thereof.
- 24. (*original*) A compound according to claim 1, wherein said compound is the S enantiomer, substantially free of the R enantiomer of said compound.
- 25. (currently amended) A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, premature ejaculation, comprising the step of:

administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Application No.: 10/659,531

Office Action Dated: October 25, 2004

- 26. (original) A method according to claim 25, wherein the condition is depression.
- 27. (*original*) A method according to claim 25, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
- 28. (original) A pharmaceutical composition, comprising:

an effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof; and

PATENT

a pharmaceutically acceptable carrier or excipient.